The bill trades stronger protections against political influence in NIH/ARPA‑H grantmaking and greater funding stability and transparency for increased administrative burdens, potential constraints on executive appointment authority, and risks to certain federal employees' protections and timely enforcement actions.
Researchers, research institutions, and taxpayers: NIH/ARPA‑H grant decisions will be less subject to political-appointee influence, protecting merit-based awards and scientific integrity.
Award recipients (universities, labs, hospitals) and their projects: Grants, contracts, and cooperative agreements are more likely to remain funded for their agreed periods because NIH must make written findings before suspending or cancelling awards.
Taxpayers and Congress: Increased transparency and oversight via required reporting on political‑employee participation and mandated notification to congressional committees of cancellations/suspensions.
Federal employees (SES noncareer, Schedule C/G, designees): More staff may be reclassified as 'political employees,' exposing them to different rules and reduced civil‑service protections and job security.
President and executive branch: The bill restricts the President's ability to place political appointees into NIH positions and may reduce executive flexibility and control over agency direction.
NIH/ARPA‑H/HHS operations and grant applicants: New tracking, reporting, and compliance requirements will create administrative burdens and costs that could divert staff time and delay processes.
Based on analysis of 5 sections of legislative text.
Prohibits political appointees from participating in NIH/ARPA‑H management and funding decisions, requires a report on past participation, and restricts cancellations or suspensions of awards.
Prohibits most political appointees from working in or making program and funding decisions at NIH and ARPA‑H, creates a statutory definition of “political employee,” requires NIH to report on recent political‑employee involvement in funding actions, and limits the agency’s ability to cancel or suspend grants and other agreements without written findings and prompt congressional notice. The measure preserves certain statutory requirements and exempts top agency directors and narrowly defined, required interagency participation.
Introduced January 21, 2026 by Diana DeGette · Last progress January 21, 2026